Publications by authors named "Elizabeth Bilotti"

Claim this Profile
P
Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.
Ajai Chari, Sarah Larson, Beata Holkova, Robert F Cornell, Cristina Gasparetto, Elizabeth Bilotti

Leuk Lymphoma· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.
Christian Buske, Shalal Sadullah, Efstathios Kastritis, Alessandra Tedeschi, Ramón García-Sanz, Elizabeth Bilotti

Lancet Haematol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.
Paul G Richardson, William I Bensinger, Carol Ann Huff, Caitlin L Costello, Nikoletta Lendvai, Elizabeth Bilotti

Br J Haematol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended follow-up with the Bruton's tyrosine kinase inhibitor ibrutinib in previously treated Waldenström's macroglobulinemia.
Richard R Furman, Ying Luan, Elizabeth Bilotti, Thorsten Graef

Leuk Lymphoma· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Steven E Coutré, Richard R Furman, Ian W Flinn, Jan A Burger, Kristie Blum, Elizabeth Bilotti

Clin Cancer Res· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.
Larysa Sanchez, David H Vesole, Joshua R Richter, Noa Biran, Elizabeth Bilotti

Br J Haematol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Meletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, Jeffrey V Matous, David Macdonald, Elizabeth Bilotti

Lancet Oncol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma.
Elizabeth Bilotti, David H Vesole, Laura McBride, Linda Schmidt, Zhijie Gao

Clin Lymphoma Myeloma Leuk· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
David H Vesole, Elizabeth Bilotti, Joshua R Richter, Ann McNeill, Laura McBride

Br J Haematol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
John C Byrd, Richard R Furman, Steven E Coutre, Jan A Burger, Kristie A Blum, Elizabeth Bilotti

Blood· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel agents for the treatment of multiple myeloma: proteasome inhibitors and immunomodulatory agents.
Sandra E Kurtin, Elizabeth Bilotti

J Adv Pract Oncol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment.
Elizabeth Bilotti

Clin J Oncol Nurs· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
Paul G Richardson, David Siegel, Rachid Baz, Susan L Kelley, Nikhil C Munshi, Elizabeth Bilotti

Blood· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma.
Madiha Tufail, David S Siegel, Laura McBride, Elizabeth Bilotti, Erica Bello

Clin Lymphoma Myeloma Leuk· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The anion gap and routine serum protein measurements in monoclonal gammopathies.
Karen H van Hoeven, Rosy E Joseph, William J Gaughan, Laura McBride, Elizabeth Bilotti

Clin J Am Soc Nephrol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survivorship care guidelines for patients living with multiple myeloma: consensus statements of the International Myeloma Foundation Nurse Leadership Board.
Elizabeth Bilotti, Beth M Faiman, Tiffany A Richards, Joseph D Tariman, Teresa S Miceli

Clin J Oncol Nurs· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Routine health maintenance in patients living with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.
Elizabeth Bilotti, Charise L Gleason, Ann McNeill,

Clin J Oncol Nurs· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of side effects of novel therapies for multiple myeloma: consensus statements developed by the International Myeloma Foundation's Nurse Leadership Board.
Page Bertolotti, Elizabeth Bilotti, Kathleen Colson, Kathleen Curran, Deborah Doss

Clin J Oncol Nurs· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Steroid-associated side effects in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.
Beth Faiman, Elizabeth Bilotti, Patricia A Mangan, Kathryn Rogers,

Clin J Oncol Nurs· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis